Oxoid Deutschland GmbH conducts wholesale and retail trade as well as manufacturing of culture media, reagents and other chemical, medical and biotech products (excluding license-required products) and holds direct and indirect equity interests in other companies. The company is part of the Specialty Diagnostics segment of Thermo Fisher Scientific Inc. and produces ready-to-use finished culture media at its Wesel site, primarily filled into Petri dishes and tubes and subject to strict quality regulations. It also acts as a distributor—particularly for Oxoid Limited (UK)—and supplies companies in Europe, the USA, Asia and Australia as well as customers from the clinical sector (hospitals, public testing institutes, private laboratories) and the industrial sector (food, pharmaceutical and cosmetics). Oxoid Deutschland GmbH holds 100% of Thermo Fisher (Kandel) GmbH and Thermo Fisher Diagnostics Sp. z o.o. (Warsaw) and performs holding functions.
der Groß- und Einzelhandel mit Nährböden und Reagenzien und anderen chemischen, medizinischen und biotechnischen Produkten, sowie deren Herstellung (jeweils ausgenommen erlaubnispflichtige Produkte) sowie der Erwerb, das Halten, das Verwalten und das Veräußern von direkten und indirekten Beteiligungen an anderen Unternehmen.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Duisburg Local Court, HRB 17871 (as of 1 November 2026)
| Name | Type | City |
|---|---|---|
| Alexander Schierholt | Geschäftsführer(in) | Xanten |
| Dalibor Sevcik | Geschäftsführer(in) | Eindhoven |
Source: German Commercial Register (Handelsregister) Duisburg Local Court, HRB 17871 (as of 1 November 2026)
| Date | Event Type | Event |
|---|---|---|
| 08.10.2012 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| 07.05.2009 | Business Address Registered | Am Lippeglacis 4 - 8, 46483 Wesel |
| 15.10.2007 | Company Name Change | Oxoid Deutschland GmbH |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 08.10.2012 | Capital Increase | +400.000 € | 426.000 € |
| 27.02.2007 | Capital Increase | +1.000 € | 26.000 € |
| 29.07.2005 | Share Capital Set | — | 25.000 € |
Source: German Commercial Register (Handelsregister) Duisburg Local Court, HRB 17871 (as of 1 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | €86,795,812 | €0 | €158,285,356 | — |
| 2024 | €92,806,243 | €13,100,105 | €161,905,623 | 225 |
| 2023 | €97,922,971 | €14,062,025 | €164,641,138 | 225 |
| 2022 | €92,741,007 | €12,025,507 | €171,149,793 | 220 |
| 2021 | €89,909,748 | €9,824,322 | €170,760,394 | 222 |
| 2020 | €80,098,000 | €16,948,000 | €152,384,000 | 206 |
| 2019 | €77,428,000 | €19,453,000 | €152,622,000 | 204 |
| 2018 | €78,552,000 | €20,972,000 | €161,191,000 | — |
| 2017 | €77,220,000 | €24,459,000 | €171,787,000 | — |
| 2016 | €70,333,000 | €17,028,000 | €145,601,000 | — |
Sign in to download data
Source: German Commercial Register (Handelsregister) Duisburg Local Court, HRB 17871 (as of 1 November 2026)
Kyberg Pharma Vertriebs-GmbH
Oberhaching · Großhandel mit pharmazeutischen Erzeugnissen
Radiometer GmbH
Krefeld · Großhandel mit medizinischen und orthopädischen Artikeln, Dental- und Laborbedarf
G. Staehle GmbH u. Co.KG
Stuttgart · Herstellung von Verpackungen und Verschlüssen aus Eisen, Stahl und NE-Metall
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €15,110,141 | 44.1% |
| Depreciation | €19,057,637 | 55.6% |
| Interest & Similar | €112,840 | 0.3% |
